HomeNewsRespiratoryCystic fibrosis

  • KALYDECO in Cystic Fibrosis receives positive CHMP opinion by EMA

    • October 21, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Positive results from new triple combinations in Cystic Fibrosis, displayed by Vertex

    • October 21, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Synspira’s drug receives FDA Orphan Designation for Cystic Fibrosis treatment

    • October 16, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • FDA Approves ORKAMBI in Cystic Fibrosis for Children Ages 2-5 Years

    • August 13, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Boehringer Ingelheim to Develop novel Gene Therapy for Cystic Fibrosis

    • August 7, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Kalydeco (ivacaftor) Data Demonstrates Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of Cystic Fibrosis

    • June 7, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more

  • Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

    • April 30, 2018
    • Posted by: Pharmascroll
    • Category:
    No Comments
    read more
SPEAK TO AN EXPERT